Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 2, 2003-01 ,pp. : 79-87

Karger

Access to resources Recommend Favorite

Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment

By  

Neuroepidemiology, Vol. 28, Iss. 2, 2007-04 ,pp. : 116-117

Karger

Access to resources Recommend Favorite

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 29-34

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

By  

Dementia and Geriatric Cognitive Disorders, Vol. 28, Iss. 5, 2009-11 ,pp. : 478-492

Karger

Access to resources Recommend Favorite